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tribute to the associated morbidity and mortality. The heterogeneity of uremic toxins with respect to
their molecular weight and protein binding may affect their removal by hemodialysis.
Objectives: To investigate the effect of high ﬂux versus low ﬂux hemodialysis (HD) on serum beta-
2-microglobulin (B2MG) and advanced oxidation protein products (AOPP) as uremic toxins and
protein carbonyl (PCO) as an oxidative stress marker in chronic HD patients.
Methods: Twenty patients on chronic low ﬂux HD were recruited from El-Shefaa Hospital in
Alexandria. At the start of the study, all patients were switched to high ﬂux HD for 8 weeks (period
A), followed by 2 weeks low ﬂux HD as a wash out period. Then, the patients had another 8 weeks
of low ﬂux HD (period B). Pre-dialysis serum samples were taken at beginning and end of period A
(pre-high ﬂux and post-high ﬂux) and at beginning and end of period B (pre-low ﬂux and post-low
ﬂux). B2MG was measured by ELISA, AOPP and PCO were assayed spectrophotometrically.tion protein products; HD,
lin; PCO, protein carbonyl.
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38 H.S. El-Wakil et al.Results: Post-high ﬂux B2MG and PCO levels were signiﬁcantly lower than pre-high ﬂux levels
(p= 0.031 and 0.036, respectively), but no signiﬁcant change was observed in AOPP (p= 0.8).
Post-low ﬂux B2MG, AOPP and PCO were all signiﬁcantly higher than pre-low ﬂux levels
(p= 0.0002, 0.019, and 0.0002, respectively). Post-low ﬂux B2MG and PCO were signiﬁcantly
higher than post-high ﬂux levels (p< 0.0001and p= 0.0005, respectively) but no signiﬁcant differ-
ence was observed in AOPP (p= 0.112). Pre-high ﬂux PCO positively correlated with AOPP
(p= 0.013) and B2MG (p= 0.01). Post-high ﬂux PCO positively correlated with B2MG
(p= 0.036).
Conclusion: High ﬂux hemodialysis results in the reduction of serum beta-2 microglobulin and pro-
tein carbonyl whereas advanced oxidation protein products are not affected. On the other hand, low
ﬂux hemodialysis is associated with increased levels of the three markers. High ﬂux hemodialysis
thus allows better removal of uremic toxins than low ﬂux hemodialysis.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
The uremic syndrome is characterized by the retention of toxins
that adversely affect various metabolic processes and contribute
to the associated morbidity and mortality. According to their
sizes and hydrophobicity, uremic toxins may be: (a) water-solu-
ble, small molecules (molecular weight <500 Da) such as urea.
These are easily removed by any dialysis approach. (b) Middle
molecules with a molecular weight >500 Da. (c) Protein-bound
hydrophobic solutes such as phenolic compounds.1,2
Middle molecules include beta-2 microglobulin (B2MG),
advanced glycation endproducts (AGE), advanced oxidation
protein products (AOPP), and other peptides. High ﬂux dialy-
sis using membranes that have large pores may allow more efﬁ-
cient removal of these large molecules than low ﬂux dialysis
that uses membranes with smaller pore sizes.2
B2MG forms the beta chain of the human leukocyte anti-
gen class I molecule. It is present on the surface of most nucle-
ated cells and in most biological ﬂuids.3 It is mainly excreted
by the kidney with negligible extra-renal elimination. B2MG
has a molecular weight of 11.8 kDa and has been widely used
for assessment of dialysis efﬁciency as regards middle molecule
removal.5 Longstanding increases in serum B2MG levels are
associated with the development of dialysis-related amyloido-
sis in patients on chronic hemodialysis.4,6
During dialysis, blood contact with dialyzer membrane re-
sults in the activation of mononuclear cells and neutrophils.
This results in the generation of large amounts of reactive oxy-
gen species. The resulting oxidative stress is implicated in the
accelerated atherogenesis and increased cardiovascular disease
seen in patients on chronic hemodialysis.7–9
Advanced oxidation protein products (AOPP) are uremic
toxins created during oxidative stress through the reaction of
chlorinated oxidants with plasma proteins.10 Oxidation of ami-
no acid residues such as tyrosine leading to formation of dity-
rosine, protein cross-linking and fragmentation as well as loss
of enzymatic or other functional properties.7,11 Advanced oxi-
dation protein products have variable molecular weights
depending on the ligand to which they are linked.1 Besides
being markers of oxidative stress, AOPP appear to have a
pro-inﬂammatory action.12
Oxidation of carbohydrates and lipids may lead to the
production of reactive carbonyl groups (RCOs). The associa-
tion of reactive oxygen species (ROS) and RCOs with proteinsresults in the formation of carbonylated dysfunctional proteins
in plasma and tissues.11 Protein carbonyl (PCO) content is
considered a good marker for oxidative stress-dependent cellu-
lar damage.13 A general increase in plasma protein carbonyls
in uremic patients has been reported.8,14 Besides, protein car-
bonyls are precursors of advanced glycation end-products
(AGE) which constitute a middle molecule toxin that plays a
vital role in the progression of renal failure.15,16
Since the heterogeneity of middle molecule uremic toxins with
respect to their molecular weight and protein binding may affect
their removal by hemodialysis, this workwas carried out to inves-
tigate the effect of high ﬂux versus lowﬂuxhemodialysis on serum
levels of uremic toxins beta-2microglobulin and advanced oxida-
tionproteinproducts aswell as the oxidative stressmarkerprotein
carbonyl in chronic hemodialysis patients.
2. Methods
Twenty patients (16 males and four females) with end stage re-
nal disease (ESRD) undergoing chronic regular hemodialysis
were recruited from El-Shefaa Hospital in Alexandria, Egypt.
All patients were in a stable clinical condition. A group of 20
healthy age-matched subjects were included as a control group.
Smokers and subjects receiving anti-inﬂammatory or antioxi-
dant therapy were excluded from the study.
Informed consent was taken from all participants in the
study. The study was approved by the ethics committee of
the Faculty of Medicine, Alexandria University.
2.1. Study design
Before starting the study, all patients had been on chronic reg-
ular low ﬂux HD. At the beginning of the study, all patients
were switched to high ﬂux HD for a period of 8 weeks (period
A). This was followed by a wash-out period (period W) of
2 weeks on low ﬂux HD to exclude carry-over effects. Patients
were then maintained on low ﬂux HD for a further period of
8 weeks (period B). Since different membrane types may have
different effects on the oxidative status in HD patients,17 both
high ﬂux and low ﬂux membranes were made of the same
material (synthetic polyamide blend membranes: polyﬂux
170H and polyﬂux 17L respectively, Gambro Co, USA).
All patients were dialyzed 3 times/week using bicarbonate
dialysate. Dialysate ﬂow rate was 500 mL/min. The duration
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tween 250–400 mL/min with a mean of 323 ± 42.2 mL/min.
Duration of HD sessions and blood ﬂow rate were varied to
reach a urea reduction ratio (URR) of > 65%.18 All patients
were on a maintenance dose of human recombinant erythro-
poietin after reaching target hemoglobin level (11–12 g/dL).
No blood transfusion was given to any patient during the
study period.
Blood samples were taken before the ﬁrst dialysis session of
the high ﬂux period A (pre-high ﬂux), another pre-dialysis
sample was taken at the end of this period (post-high ﬂux).
A third pre-dialysis sample was taken at the beginning of per-
iod B (pre-low ﬂux) and a fourth pre-dialysis sample was taken
at the end of this period (post-low ﬂux).
Full history taking and clinical examination were carried
out. In addition, complete blood picture was performed/
4 weeks. Erythropoietin dose was adjusted to maintain hemo-
globin level at 11–12 g/dL. Pre- and post-dialysis serum urea
was measured monthly once to calculate urea reduction ratio:
URR= (ureapre-dialysis  ureapost-dialysis)/ureapre-dialysis · 100.
The following laboratory tests were done on each of the
four venous blood samples obtained from each patient and
once for the control subjects:
2.1.1. Beta-2-microglobulin assay
Thiswas done by enzyme-linked immunosorbent assay (ELISA)
using a commercially available kit (DRG Microglobulin,
beta-2 EIA Kit, DRG International, Inc., USA).
2.1.2. Advanced oxidation protein products (AOPP)10
AOPP were measured spectrophotometrically. In 96-well
microtiter plates, 200 lL serum (diluted 1:5 in phosphate-
buffered saline) was acidiﬁed using 20 lL acetic acid. Absor-
bance of the reaction mixture was read immediately at
340 nm against a blank containing 200 lL PBS, 10 lL
1.16 mol/L potassium iodide, and 20 lL acetic acid. AOPP
content was determined using a standard curve constructed
with chloramine-T standard solutions (Sigma–Aldrich,
USA). AOPP concentrations are expressed in lmol/L chlora-
mine-T equivalents.
2.1.3. Protein carbonyl19
Protein carbonyl was measured spectrophotometrically using
OxiSelect protein carbonyl spectrophotometric kit (Cell
Biolabs, Inc., USA). The test is based on derivitization of pro-
tein carbonyl groups with 2,4-dinitrophenylhydrazine
(DNPH). The amount of protein-hydrozone produced is mea-
sured spectrophotometrically at 375 nm. Carbonyl levels are
expressed as nmol/mg of protein.
2.1.3.1. Procedure. Serum protein was assayed on the Dimen-
sion RXL chemistry autoanalyzer (Siemens Healthcare Diag-
nostics, Inc., USA) and was adjusted to 1 mg/mL using
distilled water. One milliliter of DNPH was added to 250 lL
of diluted serum. After incubation, protein was precipitated
using 1.25 mL trichloracetic acid 20%. The protein pellet
was washed with 1 mL ethanol/ethyl acetate (1:1 v/v) to
remove any free DNPH and was solubilized in 250 lL 1 M
NaOH. Absorbance was read at 370 nm. Carbonyl content
was calculated using molar extinction coefﬁcient of DNPH
(22 · 103 mol1 cm1). Since some protein may be lost duringthe washing steps, the protein content of the ﬁnal solubilized
pellet was measured by the Lowry method.20 Carbonyl content
was standardized to protein content and was expressed as
nmol/mg protein.
2.2. Statistical analysis
Data were analyzed using STATVIEW software version 5.1
for Windows (SAS Institute Inc., NC, USA). Comparisons
between patients and controls were done using Mann Whitney
test. Changes in studied parameters within the patients group
were analyzed using Wilcoxon signed rank test. Spearman
correlation test was used to investigate the correlation between
the studied variables. Statistical signiﬁcance was considered at
p value <0.05.
3. Results
The clinical characteristics of 20 patients on chronic hemodial-
ysis are depicted in Table 1. Hypertension was the most com-
mon cause of chronic kidney disease (30%), while the cause
was not identiﬁed in 15% of patients. Three patients (15%)
had cardiomegaly and two patients (10%) had diabetic
retinopathy. Table 2 presents baseline biochemical data of
HD patients versus controls. Serum B2MG, AOPP and PCO
were signiﬁcantly higher in HD patients than in controls
(p< 0.0001).
Signiﬁcantly lower levels of serum B2MG and PCO were
observed at the end of the high ﬂux dialysis period (post-high
ﬂux) compared to pre-high ﬂux levels. (p= 0.031 and 0.036,
respectively). On the other hand, no statistically signiﬁcant
change was observed in AOPP levels during this period
(p= 0.8). (Table 3). The mean percent change (±standard er-
ror of the mean, SEM) in B2MG, AOPP and protein carbonyl
during this period was 7.97 ± 6.84%, 1.82 ± 3.63% and
7.69 ± 5.04%, respectively (Fig. 1).
Levels of the studied parameters were comparable at the start
of high ﬂux (period A) and low ﬂux (period B) HD, indicating
the adequacy of the intervening washout period (B2MG:
p= 0.313, AOPP: p= 0.472, protein carbonyl: p= 0.66).
Signiﬁcantly higher levels of B2MG, AOPP and protein car-
bonyl were observed at the end of 8 weeks of low ﬂuxHD (post-
low ﬂux) compared to their levels at the beginning of this period
(pre-low ﬂux), (p= 0.0002, 0.019 and 0.0002, respectively)
(Table 3). Mean% change (±standard error of the mean,
SEM) during period B for B2MG, AOPP and PCO was:
30.31 ± 6.43%, 9.13 ± 3.27% and 31.03 ± 5.05%, respec-
tively (Fig. 1).
Post-low ﬂux levels of B2MG and protein carbonyls were
signiﬁcantly higher than post-high ﬂux levels (p< 0.0001
and p= 0.0005, respectively). On the other hand, no signiﬁ-
cant difference was observed in AOPP levels (p= 0.112). No
signiﬁcant change was observed in serum urea level after high
ﬂux (p= 0.41) or low ﬂux hemodialysis (p= 0.57).
At the baseline, a positive correlation was observed between
pre-high ﬂux protein carbonyl and AOPP (r= 0.569, p=
0.013). Protein carbonyl was also correlated with B2MG
(r= 0.591, p= 0.01). At the end of period A, post-high ﬂux
protein carbonyl positively correlated with B2MG (r=
0.421, p= 0.036). No other correlations were detected be-
tween the studied parameters.
Table 1 Characteristics of 20 patients on chronic
hemodialysis.
Age (years) 61.8 ± 7.5 (45–75)
Gender
Male 16 (80%)
Female 4 (20%)
Duration of CKD (years) 6.7 ± 4.3(2–17)
Duration of HD (years) 4.3 ± 2.7 (1–10)
Cause of CKD
Hypertension 6 (30%)
Gout 4 (20%)
Diabetes mellitus 3 (15%)
Ostructive uropathy 3 (15%)
Unknown 3 (15%)
Polycystic kidney 1 (5%)
Systolic blood pressure (mmHg) 130.0 ± 20.3 (80–160)
Diastolic blood pressure (mmHg) 79.0 ± 8.5 (60–90)
Results are expressed as mean ± SD (minimum–maximum) and as
number (%).
CKD: chronic kidney disease, HD: hemodialysis.
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Some of the morbidity associated with chronic hemodialysis
such as hypertension and cardiovascular disease is thoughtTable 2 Baseline biochemical data and uremic toxins in HD patien
Patients (n= 20)
Hemoglobin (g/dL) 12 ± 0.6
S. urea (mg/dL) 147.4 ± 33.4
S. creatinine (mg/dL) 8.9 ± 2.4
S. B2MG (mg/L) 75.4 ± 18.3
S. AOPP (lmol/L) 85.9 ± 11.3
S. PCO (nmol/mg protein) 1.45 ± 0.3
Results are expressed as mean ± standard deviation. Data were analyzed
B2MG: beta-2 microglobulin, PCO: protein carbonyl, HD: hemodialysis
* Statistically signiﬁcance at p< 0.05.
Table 3 B2MG, AOPP and protein carbonyls in 20 patients before
High ﬂux HD (period A, 8 weeks)
Pre-high ﬂux Post-high ﬂu
B2MG (mg/L)
Mean ± SD 75.4 ± 18.3 64.9 ± 9.5
p Value 0.031*
AOPP (lmol/L)
Mean ± SD 85.9 ± 11.3 86.5 ± 12.2
p Value 0.8
PCO (nmol/mg protein)
Mean ± SD 1.45 ± 0.29 1.3 ± 0.27
p Value 0.036*
Data were analyzed using Wilcoxon signed rank test. AOPP: advanced ox
carbonyl, HD: hemodialysis.
* Statistically signiﬁcance at p< 0.05.to result from retention of middle molecule uremic toxins that
are poorly removed by hemodialysis using low-ﬂux membranes
with small pores. Recent clinical studies suggest that enhancing
the removal of these compounds has a beneﬁcial effect on sur-
vival and the quality of life of patients with end stage renal dis-
ease. This can be accomplished by using high-ﬂux dialysis
membranes with large pore sizes, increasing dialysis frequency
or prolonging the dialysis session.21
In the present study, we explored the effect of high ﬂux ver-
sus low ﬂux hemodialysis on serum levels of beta-2 microglob-
ulin and advanced oxidation protein products as representative
middle molecules. We also investigated the levels of the oxida-
tive stress marker protein carbonyl.
In agreement with previous reports22,23 our study showed
that at the start of the study, baseline pre-dialysis serum levels
of B2MG, are considerably higher in chronic HD patients than
in controls. It has been suggested that elevated B2MG concen-
trations lead to dialysis-related amyloidosis and comorbidities
that contribute to early mortality.6,24,25 Okuno et al.25 con-
cluded that serum beta-2-microglobulin level is a signiﬁcant
independent predictor of mortality in hemodialysis patients,
suggesting the clinical importance of lowering serum beta-2-
microglobulin in these patients.
In the present study, serum B2MG levels showed a signiﬁ-
cant decrease after 8 weeks on hemodialysis using high-ﬂux
membranes whereas the use of low-ﬂux dialysis resulted in
increased levels. Similarly, several studies demonstrated thatts versus controls.
Controls (n= 20) p Value
12.3 ± 0.5 0.15
28.7 ± 6.4 <0.0001*
0.8 ± 0.17 <0.0001*
1.29 ± 0.28 <0.0001*
33.4 ± 7.9 <0.0001*
0.97 ± 0.28 <0.0001*
by Mann–Whitney test. AOPP: advanced oxidation protein products,
.
and after high ﬂux and low ﬂux HD.
Low ﬂux HD (period B, 8 weeks)
x Pre-low ﬂux Post-low ﬂux
70.5 ± 5.6 91.6 ± 20.4
0.0002*
84.7 ± 14.2 91.3 ± 13.1
0.019*
1.39 ± 0.25 1.81 ± 0.35
0.0002*
idation protein products, B2MG: beta-2 microglobulin, PCO: protein
Figure 1 Mean% change in B2MG, AOPP and PCO in
response to high ﬂux and low ﬂux HD. Results are shown as
mean ± standard error of the mean (SEM). HF: high ﬂux HD,
LF: low ﬂux HD.
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high ﬂux dialyzers than with low-ﬂux dialyzers.26–28
Due to its negligible extra-renal clearance from the circula-
tion, B2MG has been used as a marker of uremic toxins in the
‘‘middle molecule’’ range, in particular for the assessment of
dialysis efﬁciency.4 However, beta-2-microglobulin levels are
not only the result of clearance but also of inﬂammation,
which is a hallmark of uremic toxicity. In addition, several
other middle molecules are bound to proteins and, therefore,
their kinetic behavior and inter-compartmental transport is
quite different from that of beta-2-microglobulin.3,29 It is,
therefore, questionable if B2MG alone is sufﬁcient for the eval-
uation of adequate middle molecule removal in HD patients. It
is probably useful to measure other middle-molecule sub-
stances in addition to B2MG.
In the present study, AOPP were higher in HD patients
than in controls. The elevated levels of AOPP in uremic pa-
tients, especially those on HD therapy, have been previously
reported.7,30 In the present study, plasma AOPP levels were
not changed in response to 8 weeks high ﬂux hemodialysis. A
similar observation was reported by Ward et al.31 Bordoni
et al.32 observed that plasma carbonyl residues but not AOPP
were signiﬁcantly lowered in patients on high ﬂux HD. They
also noted that neither of the two markers decreased in pa-
tients on low ﬂux therapy. The absence of an effect of high ﬂux
HD on AOPP level may be related to the large molecular
weight of AOPP molecules which are the result of damage to
albumin as well as proteins of higher molecular weights.
In uremic patients, particularly those undergoing mainte-
nance HD, proteins may undergo a variety of modiﬁcations
including carbonylation. This results in defective protein func-
tion, formation of advanced glycation end products and cellu-
lar dysfunction.33 In the present study, patients on chronic HD
had signiﬁcantly higher levels of PCO content than control
subjects. Similar results have been reported by other investiga-
tors.11,14,33,34 Carbonyl stress has been shown to contribute to
long-term complications associated with chronic renal failure
and hemodialysis such as dialysis-related amyloidosis and
accelerated atherosclerosis.35
Carbonyl stress in HD patients’ results not only from ure-
mia, hemodialysis therapy may also have a relevant impact
on carbonyl balance. During HD, biochemical reactivity
following contact of blood with the dialysis membrane andthe loss of antioxidant substances, may promote carbonyl for-
mation via an increase of oxidative stress.36–38 On the other
hand, HD therapy may reduce carbonyl overload by removing
low molecular weight reactive carbonyl compounds. Pavone
et al.33 demonstrated that HD membranes possess the ability
to adsorb and carbonylate plasma proteins and concluded that
hemodialytic membranes may affect the carbonyl balance in
chronic uremic patients. The level of protein carbonyl is, there-
fore, a net result of the balance between increased production
and removal.
In the present study, serum protein carbonyl was signiﬁ-
cantly reduced at the end of the high-ﬂux hemodialysis period
while levels signiﬁcantly increased by the end of low-ﬂux
hemodialysis period. It is possible that in the case of low ﬂux
dialysis, the production of reactive carbonyl groups exceeded
the ability of the dialysis membranes to remove these groups.
This probably resulted in carbonylation of proteins whose
molecular weights are much larger than the range that could
be effectively removed by low ﬂux membranes.33
A positive correlation was observed in the present study be-
tween PCO content and B2MG levels both at baseline and
8 weeks after high ﬂux HD. An explanation of this relation
may be provided by the work of Miyata et al.39 who reported
that AGE-modiﬁed B2MG binds to AGE receptors on mono-
cytes, leading to production of cytokines and reactive oxygen
species, which in turn enhance tissue toxicity.
In conclusion, serum beta-2 microglobulin and protein car-
bonyls were signiﬁcantly reduced in response to high ﬂux
hemodialysis, whereas advanced oxidation protein products
were not affected. On the other hand, hemodialysis using
low ﬂux membranes resulted in signiﬁcantly increased levels
of the three markers. Using high ﬂux hemodialysis thus allows
improved removal of a wider spectrum of uremic toxins which
may improve the quality of life and reduce the morbidity and
mortality in patients on chronic hemodialysis.References
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